Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of garadacimab prophylaxis in children aged 2 to 11 years with hereditary angioedema
MOH_2023-04-02_012356Phase 3Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of garadacimab in hereditary angioedema (HAE) (2 arms), sponsored by CSL Behring. Primary endpoints: Treatment-emergent adverse events, Maximum concentration at steady state and 2 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2023-04-02_012356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-02_012356.